Results from an international phase 3 trial of Johnson & Johnson’s single-dose COVID-19 vaccine show it is overall 66% effective in preventing moderate to severe symptoms of COVID-19. The vaccine was 85% effective in preventing severe COVID-19 disease and 100% effective in preventing COVID-19-related hospitalizations and deaths. The vaccine has been a long-hoped for game-changer in the global fight against the pandemic because it requires only one dose, can be manufactured in billions of doses, and requires only standard refrigeration.

microgen
Read more CIDRAP…
Leave A Comment